1. Home
  2. EFT vs ALT Comparison

EFT vs ALT Comparison

Compare EFT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EFT
  • ALT
  • Stock Information
  • Founded
  • EFT 2004
  • ALT 1997
  • Country
  • EFT United States
  • ALT United States
  • Employees
  • EFT N/A
  • ALT N/A
  • Industry
  • EFT Finance Companies
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • EFT Finance
  • ALT Health Care
  • Exchange
  • EFT Nasdaq
  • ALT Nasdaq
  • Market Cap
  • EFT 327.7M
  • ALT 292.0M
  • IPO Year
  • EFT N/A
  • ALT N/A
  • Fundamental
  • Price
  • EFT $12.08
  • ALT $3.83
  • Analyst Decision
  • EFT
  • ALT Strong Buy
  • Analyst Count
  • EFT 0
  • ALT 6
  • Target Price
  • EFT N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • EFT 100.8K
  • ALT 3.0M
  • Earning Date
  • EFT 01-01-0001
  • ALT 08-12-2025
  • Dividend Yield
  • EFT 10.63%
  • ALT N/A
  • EPS Growth
  • EFT N/A
  • ALT N/A
  • EPS
  • EFT 1.73
  • ALT N/A
  • Revenue
  • EFT N/A
  • ALT $20,000.00
  • Revenue This Year
  • EFT N/A
  • ALT N/A
  • Revenue Next Year
  • EFT N/A
  • ALT $761,880.20
  • P/E Ratio
  • EFT $7.62
  • ALT N/A
  • Revenue Growth
  • EFT N/A
  • ALT N/A
  • 52 Week Low
  • EFT $11.10
  • ALT $2.90
  • 52 Week High
  • EFT $13.44
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • EFT 43.69
  • ALT 51.79
  • Support Level
  • EFT $12.00
  • ALT $3.35
  • Resistance Level
  • EFT $12.24
  • ALT $3.66
  • Average True Range (ATR)
  • EFT 0.08
  • ALT 0.19
  • MACD
  • EFT 0.01
  • ALT 0.07
  • Stochastic Oscillator
  • EFT 63.16
  • ALT 86.18

About EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest

Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: